title: Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
abstract: This study aims to investigate the prognostic factors and long-term treatment outcome in patients with early stage nasal natural killer (NK)/T-cell lymphoma. Sixty-four patients were recruited in this study, whose clinical and laboratory data were collected from hospital records. Early stage (stage IE: 51, stage IIE: 13) nasal NK/T-cell lymphoma (NNTCL) was established according to Ann Arbor staging classification. Among these patients, 23 received radiotherapy (RT) alone, the remaining 41 cases were treated with radiochemotherapy (RCT) comprised of 1-6 cycles of anthracycline-based chemotherapeutic regimens. Results show that the median overall survival (OS) time was 41 months. The 5-year OS and progression-free survival rates were 59.2 and 52.3%, respectively. The 5-year OS rate for patients who received RT alone was 57.9%, whereas that for patients who received RCT was 61.5% (P = 0.47). There is no significant difference between two treatment modalities. Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (PS) score > or = 2, local tumor invasion out of nasal cavity, and lower complete remission (CR) rates in the initial treatment were significant unfavorable independent prognostic factors. Taken together, our study suggests that RCT did not improve the survival rate of patients with early stage NNTCL. PS score before treatment, local tumor invasion out of nasal cavity, and CR rate of the primary treatment may be independent prognostic factors among the subtype lymphoma entity.
authors.affiliation: Department of Radiation Oncology, First Affiliated Hospital, Anhui Medical University, Hefei, China.
authors.forename: Hui-Hui
authors.initials: HH
authors.lastname: Ma
authors.forename: Li-Ting
authors.initials: LT
authors.lastname: Qian
authors.forename: Hai-Feng
authors.initials: HF
authors.lastname: Pan
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Zhang
authors.forename: Zhi-Hua
authors.initials: ZH
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.forename: Yu-Fei
authors.initials: YF
authors.lastname: Zhao
authors.forename: Jin
authors.initials: J
authors.lastname: Gao
authors.forename: Ai-Dong
authors.initials: AD
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D011241:Prednisone
references.citation: Blood. 1994 Sep 1;84(5):1361-92
references.pmid: 8068936
references.citation: Cancer. 1998 Aug 15;83(4):806-12
references.pmid: 9708949
references.citation: J Clin Oncol. 1998 Jan;16(1):70-7
references.pmid: 9440725
references.citation: Am J Surg Pathol. 1999 Nov;23(11):1356-69
references.pmid: 10555004
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references.pmid: 18626005
references.citation: Acta Oncol. 2001;40(1):19-23
references.pmid: 11321654
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8
references.pmid: 17049184
references.citation: Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802
references.pmid: 2004957
references.citation: Oncol Rep. 2005 Feb;13(2):265-71
references.pmid: 15643509
references.citation: Cancer. 1998 Aug 1;83(3):449-56
references.pmid: 9690537
references.citation: Cancer. 1996 May 15;77(10):2137-49
references.pmid: 8640683
references.citation: Hematol Oncol. 1992 May-Aug;10(3-4):141-7
references.pmid: 1398510
references.citation: J Clin Oncol. 1995 Mar;13(3):666-70
references.pmid: 7884427
references.citation: Cancer Res. 1971 Nov;31(11):1860-1
references.pmid: 5121694
references.citation: J Clin Oncol. 2006 Jan 1;24(1):181-9
references.pmid: 16382127
references.citation: Br J Cancer. 2005 Apr 11;92(7):1226-30
references.pmid: 15798768
references.citation: Am J Surg Pathol. 2000 Nov;24(11):1511-7
references.pmid: 11075852
references.citation: Ann Oncol. 2001 Mar;12(3):349-52
references.pmid: 11332147
references.citation: Hum Pathol. 1999 Jul;30(7):849-55
references.pmid: 10414505
references.citation: Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90
references.pmid: 12182990
references.citation: Radiother Oncol. 2001 Dec;61(3):261-9
references.pmid: 11730995
references.citation: Acta Oncol. 1997;36(3):307-11
references.pmid: 9208902
references.citation: Blood. 2004 Jan 1;103(1):216-21
references.pmid: 12933580
references.citation: Leuk Lymphoma. 2006 Jul;47(7):1274-82
references.pmid: 16923557
references.citation: Leukemia. 2001 Jul;15(7):1123-6
references.pmid: 11455983
references.citation: J Clin Oncol. 1999 Dec;17(12):3835-49
references.pmid: 10577857
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Ann Oncol. 2004 Oct;15(10):1467-75
references.pmid: 15367405
references.citation: Cancer Chemother Rep. 1966 Mar;50(3):163-70
references.pmid: 5910392
references.citation: Blood. 2005 Dec 1;106(12):3785-90
references.pmid: 16109779
references.citation: Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):599-605
references.pmid: 3417488
references.citation: Int J Surg Pathol. 2004 Oct;12(4):375-87
references.pmid: 15494863
references.citation: J Clin Oncol. 2000 Jan;18(1):54-63
references.pmid: 10623693
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: Radiother Oncol. 1996 Jan;38(1):1-6
references.pmid: 8850419
references.citation: Am J Surg Pathol. 1996 Jan;20(1):103-11
references.pmid: 8540601
references.citation: Clin Lab Haematol. 2000 Aug;22(4):215-20
references.pmid: 11012633
references.citation: Am J Pathol. 2001 Dec;159(6):2095-105
references.pmid: 11733360